REGN
Regeneron Pharmaceuticals, Inc.Thesis. REGN trades at 12.6x forward and 14.3x EV/EBITDA despite a 4-of-4 EPS beat streak (avg +20% surprise) and 19% revenue growth, a discount we view as unwarranted for a franchise anchored by Dupixent ($11.9B global run-rate) and a deepening pipeline. Net cash of $6.0B, a 0.24 beta, and 92% institutional ownership underpin a defensive-growth profile; the risk is EYLEA biosimilar/competitive erosion, already partly in the price. We rate the shares BUY to a $785 target.
Scoreboard
At $676.23 REGN sits 17.6% below its 52-week high ($821.11) and 25.8% above the low ($537.45), roughly mid-range (position 0.49) with a $70.9B market cap and just $62.8B EV after $6.0B net cash. The stock has reclaimed its 50-day ($653.81) but remains below the 200-day ($700.73), signaling a base still forming. Sell-side mean target of $822 implies 21.6% upside, though a wave of early-July PT trims (Truist $769, Cantor $750, HSBC $880) argues for a more measured $785 objective.
QoQ Changes
Q1 2026 revenue of $3.61B fell 7.2% QoQ from $3.88B in Q4 2025, with basic EPS of $6.99 down from $8.21 — typical Q1 seasonality after a strong Q4. On the Finnhub basis, adjusted EPS of $9.47 still beat consensus of $9.12 by 3.9%, extending the beat streak to four straight.
Operating margin held at 20.7% in Q1 2026 ($744.8M on $3.61B), while EBITDA margin compressed to 26.8% from 30.9% in Q4 — a step down from the 45-52% operating prints seen mid-2025. Reported gross profit of $2.94B (81% of sales) remains robust despite the sequential revenue dip.
Trailing FCF margin of 21.9% and a 4.6% FCF yield confirm high cash conversion typical of a scaled biologics franchise. Operating cash generation comfortably funds R&D reinvestment without balance-sheet strain.
REGN carries $8.75B cash ($86.04/share) against just $2.71B debt, for $6.0B net cash and a fortress current ratio of 3.57 (quick 2.84). Debt/equity of 8.6% is immaterial against $31.7B of book equity ($308.33/share).
Shares change hands at 12.6x forward and 15.9x trailing earnings, 14.3x EV/EBITDA and 4.75x sales — a discount to large-cap biotech peers and to REGN's own history. A 1.12 PEG on 19% top-line growth screens outright cheap for the quality on offer.
Regeneron was tapped for the FDA's PreCheck pilot alongside Eli Lilly, potentially shaving up to 14 months off facility reviews, and secured FDA Priority Review plus EMA acceptance for cemdisiran in generalized myasthenia gravis. Collaborations span Alnylam (RNAi), Intellia/Tessera (gene editing), Hansoh (GLP-1/GIP) and Telix (radiopharma), broadening optionality beyond the core eye/immunology base.
Ownership & Insider Activity
Institutions own 92.2% of the float — BlackRock (8.69%), Vanguard (6.46%) and State Street (4.53%) anchor a high-conviction holder base — while insiders hold just 2.03%. Finnhub SEC Form 4 data shows only de minimis open-market selling by director Arthur F. Ryan (net -$186,897 across small lots at $702-780), a routine liquidity pattern rather than a signal. Short interest is modest at 3.33% of float (2.72 days to cover), though shares short ticked up to 3.30M from 2.78M the prior month.
Recent Insider Transactions
| Date | Insider | Position | Shares | Value |
|---|---|---|---|---|
| 2026-05-01 | RYAN ARTHUR F. | Director | 100 | $70.5K |
| 2026-04-01 | RYAN ARTHUR F. | Director | 100 | $77.7K |
| 2026-03-02 | RYAN ARTHUR F. | Director | 100 | $78.5K |
| 2026-02-19 | ZOGHBI HUDA Y | Director | 1,638 | $617.0K |
| 2026-02-19 | ZOGHBI HUDA Y | Director | 1,638 | $1.3M |
| 2026-02-09 | PITOFSKY JASON | Officer | 1,000 | $492.0K |
Earnings Quality
| Period | Actual EPS | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
| 2026-03-31 Q1 | $9.47 | $9.12 | +$0.35 | +3.88% |
| 2025-12-31 Q4 | $11.44 | $10.83 | +$0.61 | +5.65% |
| 2025-09-30 Q3 | $11.83 | $9.78 | +$2.05 | +20.96% |
| 2025-06-30 Q2 | $12.89 | $8.61 | +$4.28 | +49.77% |
REGN beat consensus in all four of the last four quarters with an outsized average surprise of +20.1% — a hallmark of durable execution and conservative guidance that supports an earnings-quality premium.
Surprise magnitude is narrowing sharply — from +49.8% (Q2 2025) and +21.0% (Q3) to +5.7% (Q4) and +3.9% (Q1 2026) — indicating analysts have recalibrated upward and the easy beats are behind, even as the streak persists.
Analyst Action
| Month | Distribution | Strong Buy | Buy | Hold | Sell | Strong Sell |
|---|---|---|---|---|---|---|
| 2026-07 | 9 | 18 | 11 | 0 | 0 | |
| 2026-06 | 9 | 18 | 11 | 0 | 0 | |
| 2026-05 | 11 | 19 | 8 | 0 | 0 | |
| 2026-04 | 11 | 19 | 8 | 0 | 0 |
Rating composition has softened modestly: Strong Buy slipped from 11 (Apr-May) to 9 (Jun-Jul) and Buy from 19 to 18, while Hold rose from 8 to 11 — a net -3 bullish drift with zero Sell ratings. Benchmark's July upgrade to Buy partially offset the PT cuts.
Momentum is mildly bearish on rating mix and price targets, but the book remains firmly constructive with no bearish ratings on the tape.
Seven Essential Metrics
29.6% net margin, 29.4% EBITDA margin and 14.5% ROE on a low-leverage base reflect premium biologics economics.
Revenue growing 19% YoY, but earnings contracted 7.2% and quarterly earnings fell 10.1% as EYLEA pressure and reinvestment bite.
21.9% FCF margin and 4.6% FCF yield underpin self-funded R&D and optional capital returns.
$6.0B net cash, 8.6% debt/equity and 3.57x current ratio — effectively unlevered.
0.24 beta, fortress liquidity and no bankruptcy risk make this a defensive biotech holding.
12.6x forward P/E, 14.3x EV/EBITDA and 4.75x sales sit below peer and historical norms on 19% growth.
Shares outstanding of 103.0M with active buyback history and no equity overhang; net cash supports continued repurchase.
Capital is directed to R&D and buybacks rather than a dividend, consistent with a compounding biotech.
Competitive Snapshot
| Company | EBITDA Margin | 3Y Rev CAGR | FCF Margin | Leverage | Fwd P/E |
|---|---|---|---|---|---|
VRTX Vertex Pharmaceuticals | ~45% | ~10% | ~30% | Net cash | ~24x |
AMGN Amgen Inc. | ~48% | ~10% | ~30% | ~3x | ~14x |
GILD Gilead Sciences | ~45% | ~3% | ~30% | ~1.5x | ~13x |
BIIB Biogen Inc. | ~35% | ~-3% | ~20% | <1x | ~9x |
REGN's 19% revenue growth outpaces most large-cap biotech peers, yet its 12.6x forward multiple is below Vertex and roughly level with Amgen and Gilead — an anomaly given its superior top-line trajectory and net-cash balance sheet. Versus a stalling Biogen, REGN offers growth without the pipeline-cliff discount; versus Vertex it offers valuation without sacrificing much growth. The setup is a quality name priced like a decelerator.
Business & Strategy
The franchise now pivots on Dupixent (dupilumab), which crossed $11.9B in global sales with expanding indications including COPD, increasingly offsetting maturing EYLEA anti-VEGF revenue facing competition and biosimilar risk. Libtayo (oncology), Praluent, Kevzara and the EYLEA 8mg upgrade round out a diversifying commercial base.
End demand runs through retinal specialists, dermatologists, allergists, oncologists and payers across the U.S. and ex-U.S. markets via Sanofi and Bayer partnerships.
Product sales are supplemented by collaboration revenue and profit-sharing (notably Sanofi on Dupixent/Libtayo and Bayer on EYLEA outside the U.S.). Milestone and royalty flows from Alnylam, Intellia and other alliances add optionality.
R&D intensity and manufacturing scale-up are the dominant cost drivers, partially de-risked by the FDA PreCheck facility pilot.
Regeneron's VelociSuite antibody-discovery and Genetics Center platforms create a durable, hard-to-replicate engine that has repeatedly translated into first- and best-in-class biologics. Deep clinical data, patent protection and Sanofi/Bayer distribution reinforce a wide moat, though single-asset concentration in Dupixent and EYLEA is the key vulnerability.
Monetary-Policy Sensitivity
- Low 0.24 beta dampens rate-driven repricing
- Long-duration pipeline value modestly benefits from lower discount rates
- Defensive healthcare demand is rate-insensitive
As a low-beta, net-cash defensive, REGN is only marginally sensitive to rate moves; lower rates lift the present value of its long-dated pipeline but do little to the near-term earnings base. Any benefit is more likely to come from a biotech risk-on rotation than from duration mechanics alone.
SWOT Analysis
- Dupixent blockbuster at ~$11.9B global run-rate with expanding indications
- $6.0B net cash and 21.9% FCF margin — self-funding R&D
- Flawless 4-of-4 beat streak with +20% average surprise
- Proprietary VelociSuite/Genetics discovery platform
- Earnings declining (-7.2% YoY) despite revenue growth
- Heavy concentration in Dupixent and EYLEA
- Narrowing EPS surprise magnitude signals fading upside
- EBITDA margin compression QoQ (30.9% to 26.8%)
- FDA PreCheck pilot could accelerate manufacturing approvals by ~14 months
- Cemdisiran Priority Review/EMA acceptance in myasthenia gravis
- Gene-editing and RNAi optionality via Intellia, Tessera, Alnylam
- Cramer-flagged biotech M&A wave could re-rate the sector
- EYLEA biosimilar and anti-VEGF competitive erosion
- Sell-side PT cuts (Truist, Cantor, HSBC) signal cooling estimates
- Pricing/policy risk across U.S. drug reimbursement
- New Dupixent challengers (e.g., Talawar's TALA-125) entering the immunology arena
Catalysts & Event Risks
- Q2 2026Q2 2026 earnings
Next print tests whether the four-quarter beat streak survives against tougher comps and EYLEA erosion.
- Q3 2026Cemdisiran regulatory decisions
FDA Priority Review and EMA action on cemdisiran in generalized myasthenia gravis could open a new indication.
- H2 2026Dupixent indication expansion
Continued label growth (COPD and beyond) drives the core growth narrative.
- H2 2026FDA PreCheck progress
Facility-review acceleration under the pilot supports supply and margin outlook.
- Q4 2026Pipeline/M&A optionality
A sector M&A wave and gene-editing readouts could re-rate the multiple.
The near-term swing factor is Q2 earnings against a narrowing surprise trend, while cemdisiran and Dupixent label expansions provide the medium-term re-rating fuel. A biotech M&A wave, if Cramer's call proves right, is a free option on the sector.
Technical Analysis
REGN has recovered off the $537 low to $676, reclaiming the 50-day ($653.81) but stalling beneath the 200-day ($700.73), a classic basing pattern. Sitting mid-range (position 0.49) with volume near average (918k vs 1.00M), the setup favors accumulation into the $650s. A decisive break above $700 opens the path toward the $785 target and the $821 prior high; failure to hold $650 risks a retest of the $600 zone. Risk-reward skews favorably given ~16% upside to target against defined support just below.
Verdict
Macro context. Large-cap biotech is being flagged as 'the hottest group in the market' with expectations of an M&A flood, providing a supportive sector tailwind for a defensive, low-beta name. A softer-rate backdrop and healthcare's demand inelasticity further insulate REGN from macro volatility.
REGN pairs 19% revenue growth, a flawless beat streak and a $6.0B net-cash balance sheet with a 12.6x forward multiple that prices in more EYLEA erosion than the numbers justify. The bear case — decelerating EPS, narrowing surprises and sell-side PT trims — is real but already reflected, while Dupixent's $11.9B franchise, cemdisiran optionality and a re-igniting biotech M&A cycle offer asymmetric upside. We rate the shares BUY to $785 (16% upside), with defined support in the $650s underpinning an attractive risk-reward.
Data source: Yahoo Finance / yfinance · fetched 7/8/2026, 9:49:31 AM